Business Context and Reporting Period
DarioHealth Corp. (DRIO) filed a Form 8-K on March 23, 2020, reporting an event that occurred on March 17, 2020. The company, incorporated in Delaware and headquartered in Israel, is an emerging growth company. The filing details an unregistered sale of equity securities in the form of a warrant issued to The Vitality Group, LLC ("Vitality") pursuant to an amended professional services agreement.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the terms of a specific equity issuance.
- Security Issued: Warrant to purchase up to 500,000 shares of Common Stock.
- Exercise Price: $5.94 per share (a 25% premium to the March 17, 2020 closing price).
- Maximum Annual Cap: No more than 125,000 Warrant Shares may be exercisable in any given fiscal year.
- Exercise Period: Three years after the shares become exercisable.
Material Changes and Vesting Terms
The material change reported is the issuance of the warrant, which is subject to performance-based vesting tied to annual revenues generated from Vitality's customers. The vesting schedule is as follows:
- 2020: Threshold of $500,000 revenue. Base award of 25,000 shares plus 1 share for every additional $20 in revenue above the threshold.
- 2021: Threshold of $1,000,000 revenue. Base award of 25,000 shares plus 1 share for every additional $40 in revenue above the threshold.
- 2022: Threshold of $1,500,000 revenue. Base award of 25,000 shares plus 1 share for every additional $60 in revenue above the threshold.
- 2023: Threshold of $2,000,000 revenue. Base award of 25,000 shares plus 1 share for every additional $80 in revenue above the threshold.
Guidance, Risks, and Unusual Items
The filing does not provide forward-looking guidance, management commentary on operations, or a discussion of general risks. However, it notes specific legal contingencies:
- Registration Exemption: The warrant was issued under Section 4(a)(2) of the Securities Act of 1933 as a private placement not involving a public offering.
- Resale Restrictions: The warrant and underlying shares are unregistered and may not be sold in the United States absent registration or an applicable exemption.
- Legal Disclaimer: The report does not constitute an offer to sell or a solicitation of an offer to buy the securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of DRIO common stock relative to the $5.94 exercise price to assess immediate dilution potential.
- Review the full text of the Warrant (Exhibit 4.1) for specific adjustment mechanisms and termination clauses.
- Monitor future filings to track actual revenue generated from Vitality's customers against the annual vesting thresholds.
- Confirm the total number of shares outstanding to calculate the potential dilution impact of the 500,000 warrant shares.